tranilast

Description: Tranilast (also known as MK 341; SB 252218; trade name Rizaben), an analog of a tryptophan metabolite, is an antiallergic drug developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s. Tranilast acts by inhibiting the production of interleukin-6 in endothelial cells. It acts by reducing collagen synthesis in fibroblasts and inhibiting growth of neurofibroma cells. Initially, tranilast was identified as an anti-allergic agent, and used in the treatment of inflammatory diseases, such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids and hypertrophic scars. Subsequently, the results showed that it could be also effective in the management of a wide range of conditions. The beneficial effects of tranilast have also been seen in a variety of disease states, such as fibrosis, proliferative disorders, cancer, cardiovascular problems, autoimmune disorders, ocular diseases, diabetes and renal diseases.

References: PLoS One. 2018 Oct 11; 13(10):e0203742.

Related CAS:70806-55-2 (Trans-Tranilast); 104931-56-8 (sodium salt)